IN2014MU01194A - - Google Patents

Info

Publication number
IN2014MU01194A
IN2014MU01194A IN1194MU2014A IN2014MU01194A IN 2014MU01194 A IN2014MU01194 A IN 2014MU01194A IN 1194MU2014 A IN1194MU2014 A IN 1194MU2014A IN 2014MU01194 A IN2014MU01194 A IN 2014MU01194A
Authority
IN
India
Prior art keywords
acceptable derivative
pharmaceutical
sulbactam
cefepime
stereoisomer
Prior art date
Application number
Inventor
Sachin Bhagwat
Mahesh Vithalbhai Patel
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Priority to CN201580017231.6A priority Critical patent/CN106900171A/en
Priority to EP15706531.9A priority patent/EP3125887A1/en
Priority to MX2016012646A priority patent/MX2016012646A/en
Priority to PCT/IB2015/050268 priority patent/WO2015150926A1/en
Priority to IN1194MU2014 priority patent/IN2014MU01194A/en
Priority to JP2016558575A priority patent/JP2017508769A/en
Priority to KR1020167027684A priority patent/KR20160130824A/en
Priority to BR112016022439A priority patent/BR112016022439A2/en
Priority to US15/300,113 priority patent/US20170151221A1/en
Publication of IN2014MU01194A publication Critical patent/IN2014MU01194A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmaceutical compositions comprising a beta-lactam compound selected from cefepime, sulbactam or a pharmaceutically acceptable derivative thereof, and a compound of Formula (I) or a stereoisomer or a pharmaceutical acceptable derivative thereof, are disclosed.
IN1194MU2014 2014-03-29 2015-01-14 IN2014MU01194A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN201580017231.6A CN106900171A (en) 2014-03-29 2015-01-14 Pharmaceutical composition comprising Cefepime or Sulbactam
EP15706531.9A EP3125887A1 (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam
MX2016012646A MX2016012646A (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam.
PCT/IB2015/050268 WO2015150926A1 (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam
IN1194MU2014 IN2014MU01194A (en) 2014-03-29 2015-01-14
JP2016558575A JP2017508769A (en) 2014-03-29 2015-01-14 Pharmaceutical composition comprising cefepime or sulbactam
KR1020167027684A KR20160130824A (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam
BR112016022439A BR112016022439A2 (en) 2014-03-29 2015-01-14 PHARMACEUTICAL COMPOSITIONS COMPRISING CEFEPIM OR SULBACTAM
US15/300,113 US20170151221A1 (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1194MU2014 IN2014MU01194A (en) 2014-03-29 2015-01-14

Publications (1)

Publication Number Publication Date
IN2014MU01194A true IN2014MU01194A (en) 2015-10-02

Family

ID=54239460

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1194MU2014 IN2014MU01194A (en) 2014-03-29 2015-01-14

Country Status (9)

Country Link
US (1) US20170151221A1 (en)
EP (1) EP3125887A1 (en)
JP (1) JP2017508769A (en)
KR (1) KR20160130824A (en)
CN (1) CN106900171A (en)
BR (1) BR112016022439A2 (en)
IN (1) IN2014MU01194A (en)
MX (1) MX2016012646A (en)
WO (1) WO2015150926A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115151544A (en) * 2020-09-01 2022-10-04 宁夏农林科学院 Beta-lactamase inhibitors and preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555075A (en) * 2004-12-02 2011-02-25 Venus Remedies Ltd Compositions for combating beta-lactamase-mediated antibiotic resistance using ceftriaxone, sulbactam and EDTA
JP5767745B2 (en) * 2011-05-28 2015-08-19 ウォックハート リミテッド Composition comprising antibacterial agent and tazobactam
CN103687598B (en) * 2011-07-26 2016-03-16 沃克哈特有限公司 Comprise the pharmaceutical composition of sulbactam and beta-lactamase inhibitor
EP2768503A1 (en) * 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
JP5666743B2 (en) * 2011-08-27 2015-02-12 ウォックハート リミテッド 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
CA2881169C (en) * 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

Also Published As

Publication number Publication date
WO2015150926A1 (en) 2015-10-08
MX2016012646A (en) 2016-10-28
BR112016022439A2 (en) 2017-08-15
US20170151221A1 (en) 2017-06-01
EP3125887A1 (en) 2017-02-08
JP2017508769A (en) 2017-03-30
CN106900171A (en) 2017-06-27
KR20160130824A (en) 2016-11-14

Similar Documents

Publication Publication Date Title
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
EP3565550A4 (en) Pharmaceutical compositions comprising meloxicam
TW201613911A (en) Heterocyclic compounds and uses thereof
PH12016502255A1 (en) Combination
JOP20200122B1 (en) Compounds useful for inhibiting cdk7
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2018002986A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
EP3621621A4 (en) Pharmaceutical compositions comprising meloxicam
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MX2016015565A (en) Certain protein kinase inhibitors.
MX2016013431A (en) Pharmaceutical compositions comprising antibacterial agents.
MX2018014813A (en) Antibacterial compositions.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
NZ739518A (en) Compounds useful for inhibiting ror-gamma-t
TW201613898A (en) Benzofuran analogue as NS4B inhibitor
IN2014MU00859A (en)
IN2013MU03421A (en)
IN2013MU03704A (en)
IN2013MU03422A (en)
IN2013MU03309A (en)
IN2014MU01194A (en)
IN2013MU03308A (en)
MX2018010652A (en) Pharmaceutical compositions.
MX2016013428A (en) Pharmaceutical compositions comprising antibacterial agents.